Sight Sciences, Inc. SGHT
We take great care to ensure that the data presented and summarized in this overview for Sight Sciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SGHT
View all-
Kck Ltd. Tortola, D84.65MShares$16.2 Million22.26% of portfolio
-
Ubs Group Ag2.53MShares$8.84 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.12MShares$7.4 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.1MShares$7.35 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$5.9 Million0.0% of portfolio
-
Jackson Square Partners, LLC San Francisco, CA918KShares$3.2 Million0.5% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR865KShares$3.02 Million0.2% of portfolio
-
Geode Capital Management, LLC Boston, MA784KShares$2.74 Million0.0% of portfolio
-
Divisadero Street Capital Management, LP Miami, FL713KShares$2.49 Million0.61% of portfolio
-
Apollo Management Holdings, L.P. New York, NY672KShares$2.34 Million0.06% of portfolio
Latest Institutional Activity in SGHT
Top Purchases
Top Sells
About SGHT
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Insider Transactions at SGHT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 08
2025
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,810
-1.18%
|
$5,430
$3.26 P/Share
|
|
Jan 08
2025
|
David Badawi Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
3,829
-0.22%
|
$11,487
$3.26 P/Share
|
|
Jan 07
2025
|
Paul Badawi President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,047
-0.21%
|
$36,141
$3.58 P/Share
|
|
Jan 03
2025
|
Alison Bauerlein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,102
-2.57%
|
$30,306
$3.52 P/Share
|
|
Jan 03
2025
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,864
-3.07%
|
$14,592
$3.52 P/Share
|
|
Jan 03
2025
|
David Badawi Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
3,111
-0.18%
|
$9,333
$3.52 P/Share
|
|
Jan 02
2025
|
Paul Badawi President and CEO |
SELL
Open market or private sale
|
Direct |
12,236
-0.21%
|
$36,708
$3.6 P/Share
|
|
Dec 06
2024
|
Manohar K. Raheja EVP, Research & Development |
BUY
Open market or private purchase
|
Direct |
5,000
+4.31%
|
$15,000
$3.85 P/Share
|
|
Dec 03
2024
|
Manohar K. Raheja EVP, Research & Development |
BUY
Open market or private purchase
|
Direct |
3,376
+3.09%
|
$10,128
$3.89 P/Share
|
|
Nov 29
2024
|
Manohar K. Raheja EVP, Research & Development |
BUY
Open market or private purchase
|
Direct |
4,624
+4.31%
|
$13,872
$3.99 P/Share
|
|
Nov 21
2024
|
Staffan Encrantz |
BUY
Open market or private purchase
|
Indirect |
551,802
+10.77%
|
$1,655,406
$3.73 P/Share
|
|
Nov 21
2024
|
Staffan Encrantz |
SELL
Open market or private sale
|
Indirect |
551,802
-46.59%
|
$1,655,406
$3.73 P/Share
|
|
Nov 19
2024
|
Manohar K. Raheja EVP, Research & Development |
BUY
Open market or private purchase
|
Direct |
2,000
+2.0%
|
$6,000
$3.7 P/Share
|
|
Nov 12
2024
|
Manohar K. Raheja EVP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
96,000
+50.0%
|
$384,000
$4.59 P/Share
|
|
Nov 12
2024
|
Brenton Taylor EVP, Operations |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+50.0%
|
$640,000
$4.59 P/Share
|
|
Oct 21
2024
|
Matthew Link Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
21,831
-3.19%
|
$109,155
$5.61 P/Share
|
|
Oct 18
2024
|
Matthew Link Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
20,487
-2.9%
|
$102,435
$5.98 P/Share
|
|
Oct 17
2024
|
Matthew Link Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
20,970
-2.89%
|
$104,850
$5.84 P/Share
|
|
Oct 16
2024
|
Matthew Link Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
20,734
-2.77%
|
$103,670
$5.91 P/Share
|
|
Oct 02
2024
|
Paul Badawi President and CEO |
SELL
Open market or private sale
|
Direct |
12,727
-0.22%
|
$63,635
$5.99 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 360K shares |
|---|---|
| Open market or private purchase | 567K shares |
| Open market or private sale | 817K shares |
|---|---|
| Grant, award, or other acquisition | 1.12M shares |
| Payment of exercise price or tax liability | 12K shares |